Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
7 hedge funds and large institutions have $9.87M invested in Soleno Therapeutics in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
3% less capital invested
Capital invested by funds: $10.2M → $9.87M (-$293K)
30% less funds holding
Funds holding: 10 → 7 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$12.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.94K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$91 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$35.7K |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$11.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $8.65M | -$11.4K | -125 | -0.1% |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $581K | -$35.7K | -391 | -6% |
|
|
BG
3
Bollard Group
Boston,
Massachusetts
| $468K | – | – | – |
|
|
BIT
4
BlackRock Institutional Trust
San Francisco,
California
| $87K | – | – | – |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $71K | +$9.94K | +109 | +15% |
|
|
VKH
6
Virtu KCG Holdings
New York
| $12K | +$12.4K | +136 | New |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$91 | +1 | +9% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$5K | -60 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$3K | -32 | Closed |
|
SLNO Hedge Fund Activity: Q2 2016 in Review
7 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2016, worth a combined $9.87M — down 2.9% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SLNO and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $12.4K. The largest seller was Sabby Management, cutting an estimated $35.7K.
- 7 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2016, down from 10 in Q1 2016.
- Funds reported $9.87M of Soleno Therapeutics stock for Q2 2016, down 2.9% quarter-over-quarter.
- 1 fund opened new Soleno Therapeutics positions in Q2 2016 and 4 closed out, a net change of -3 holders.
- The largest Soleno Therapeutics buyer in Q2 2016 was Virtu KCG Holdings, an estimated $12.4K added.
- The largest Soleno Therapeutics seller in Q2 2016 was Sabby Management, an estimated $35.7K sold.
Based on aggregated 13F filings for Q2 2016.